当前位置:首页 - 行情中心 - 多瑞医药(301075) - 财务分析 - 利润表

多瑞医药

(301075)

  

流通市值:5.71亿  总市值:16.66亿
流通股本:2742.37万   总股本:8000.00万

利润表

报告期2023-09-302023-06-302023-03-312022-12-31
公司类型通用通用通用通用
一、营业总收入246,256,774.84170,393,701.0678,085,173.39401,049,788.47
营业收入246,256,774.84170,393,701.0678,085,173.39401,049,788.47
利息收入-0--
已赚保费-0--
手续费及佣金收入-0--
二、营业总成本239,577,465.5163,038,293.8281,960,671.26388,452,256.83
营业成本71,789,330.8748,951,320.7527,537,913.3892,317,488.02
利息支出-0--
手续费及佣金支出-0--
退保金-0--
赔付支出净额-0--
提取保险合同准备金净额-0--
保单红利支出-0--
分保费用-0--
税金及附加2,767,321.361,792,408.09695,747.174,643,469.62
销售费用122,842,695.7583,361,204.539,048,134.19230,823,185.18
管理费用30,847,249.9818,962,096.339,158,260.2841,940,256.27
研发费用14,753,007.112,402,471.926,839,149.526,452,560.84
财务费用-3,422,139.56-2,431,207.77-1,318,533.26-7,724,703.1
其中:利息费用2,324,663.311,500,691.43825,466.721,360,353.35
其中:利息收入5,802,521.243,196,540.322,152,976.19,289,150.06
加:公允价值变动收益-0--
加:投资收益4,082,226.821,365,273.82852,902.1811,344.86
净敞口套期收益-0--
汇兑收益-0--
资产处置收益22,4680--
资产减值损失(新)-774,624.96-600,272.52--362,970.42
信用减值损失(新)-1,967,674.59-1,914,051.92-10,594.27-2,697,435.01
其他收益12,096,440.938,519,330669,131.6311,707,817.8
营业利润平衡项目0000
四、营业利润20,138,145.5414,725,686.62-2,364,058.3321,256,288.87
加:营业外收入751,765.65662,587.436,263.518,080.47
减:营业外支出468,949.55369,283.593,879.36249,534.35
利润总额平衡项目0000
五、利润总额20,420,961.6415,018,990.43-2,331,674.1921,024,834.99
减:所得税费用2,766,997.51,611,507.33189,0372,440,981.98
六、净利润17,653,964.1413,407,483.1-2,520,711.1918,583,853.01
持续经营净利润17,653,964.1413,407,483.1-2,520,711.1918,583,853.01
终止经营净利润-0--
归属于母公司股东的净利润19,310,802.0314,366,348.89-2,417,228.8320,502,175.07
少数股东损益-1,656,837.89-958,865.79-103,482.36-1,918,322.06
(一)基本每股收益0.240.18-0.030.26
(二)稀释每股收益0.240.18-0.030.26
八、其他综合收益7,901,3857,901,3857,901,385-1,295,827.14
归属于母公司股东的其他综合收益7,901,3857,901,3857,901,385-1,295,827.14
九、综合收益总额25,555,349.1421,308,868.15,380,673.8117,288,025.87
归属于母公司股东的综合收益总额27,212,187.0322,267,733.895,484,156.1719,206,347.93
归属于少数股东的综合收益总额-1,656,837.89-958,865.79-103,482.36-1,918,322.06
公告日期2023-10-272023-08-252023-04-252023-04-25
审计意见(境内)标准无保留意见
TOP↑